Weigl, Paul http://orcid.org/0000-0001-7434-7988
Trimpou, Georgia
Hess, Pablo
Kolinski, Martin
Bellucci, Gionata http://orcid.org/0000-0002-1240-8340
Trisciuoglio, Davide http://orcid.org/0009-0004-6173-9295
Friberg, Bertil http://orcid.org/0000-0001-7890-1210
Leziy, Sonia
Al-Nawas, Bilal http://orcid.org/0000-0002-8665-5803
Wagner, Wilfried
Pozzi, Alessandro http://orcid.org/0000-0002-3052-8186
Ottria, Liliana http://orcid.org/0000-0002-9247-4507
Wiltfang, Jörg
Behrens, Eleonore
Vasak, Christoph http://orcid.org/0000-0002-7935-6186
Zechner, Werner http://orcid.org/0000-0002-4142-9992
Funding for this research was provided by:
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 31 January 2024
Accepted: 14 July 2024
First Online: 31 July 2024
Declarations
:
: The study was performed according to the Declaration of Helsinki. Each investigator received Ethics Committee approval for their study sites. Each subject gave written informed consent. This trial was registered with ClinicalTrials.gov (NCT02184845).
: P. Weigl, (A) Pozzi, and W. Zechner serve as Key Experts for Nobel Biocare, S. Leziy and (B) Al-Nawas formerly served in this role, while other authors declare no conflict of interests.